Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis
Abstract Background: At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We…
Abstract Background: At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We…
Abstract Cannabinoids may help people with PD to manage their symptoms. Acceptability of cannabis and cannabidiol was high in French…
Abstract Background: Large-scale longitudinal studies with biological samples are needed to examine the associations between prenatal cannabis use and birth…
Abstract Introduction: The legalization of cannabidiol (CBD) across the United States, in varying degrees, has made CBD easily accessible to…
Abstract Background: Cannabidiol (CBD) is a promising novel candidate treatment for psychosis. It has a more benign side effect profile…
Abstract Hemp seed flour (HSF) is a by-product of the hemp oil production process and is a valuable source of…
Abstract Background: We have piloted a new online knowledge translation (KT) program created to educate youth about cannabis effects, which…
Abstract Purpose: The linkage between patient‐reported data and medico‐administrative claims is of great interest for epidemiologic research. The goal of…
Abstract Background: The persistence of cannabis use disorder (CUD) in young adults with first-episode psychosis (FEP) is associated with poor…
Abstract Background: Unlike other plants, Cannabis sativa is excluded from regulation by the United States Department of Agriculture (USDA). Distinctive…